PDGFRA and glioblastoma: Despite significant drug concentrations reached inside the glioblastoma [69], imatinib has shown limited efficacy in recurrent or newly diagnosed glioblastoma in adults [70] and response to the drug was not increased in patients with PDGFRA immunopositivity [71].